CSBio CSBio

X
[{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","amount":"$2,020.0 million","upfrontCash":"$20.0 million","newsHeadline":"Silence Therapeutics Achieves Another Research Milestone Payment from Mallinckrodt Collaboration for Complement-Mediated Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Silence Therapeutics"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quell Therapeutics Granted CTA Approval to Begin First Clinical Trial with a Multi-modular Engineered Treg Cell Therapy","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Quell Therapeutics"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"Jeito Capital","pharmaFlowCategory":"D","amount":"$156.0 million","upfrontCash":"Undisclosed","newsHeadline":"Quell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Quell Therapeutics"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"AGC Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Allergy Therapeutics Selects AGC Biologics to Manufacture Novel Peanut Allergy Vaccine Candidate","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Allergy Therapeutics"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","amount":"$2,024.0 million","upfrontCash":"$20.0 million","newsHeadline":"Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Silence Therapeutics"},{"orgOrder":0,"company":"MiroBio","sponsor":"Medicxi","pharmaFlowCategory":"D","amount":"$97.0 million","upfrontCash":"Undisclosed","newsHeadline":"MiroBio Raises $97 Million Series B Financing to Develop Checkpoint Agonists for Treatment of Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"MiroBio"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Funds will primarily be used to advance MiroBio’s two lead antibody candidates into clinical trials and obtain safety and efficacy data in patients with autoimmune diseases. MB272 and MB151 are differentiated, precision-engineered checkpoint receptor agonists for BTLA & PD-1.

            Lead Product(s): MB272

            Therapeutic Area: Immunology Product Name: MB272

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Medicxi

            Deal Size: $97.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing June 29, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply.

            Lead Product(s): VLP Peanut

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Vaccine

            Partner/Sponsor/Collaborator: AGC Biologics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership March 31, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the collaboration, Silence is responsible for executing the development program for SLN501 until the end of 1 phase I, after which Mallinckrodt will assume responsibility for clinical development and global commercialization.

            Lead Product(s): SLN501

            Therapeutic Area: Immunology Product Name: SLN501

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Mallinckrodt Pharmaceuticals

            Deal Size: $2,024.0 million Upfront Cash: $20.0 million

            Deal Type: Collaboration March 23, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Proceeds to be used to fund clinical development of QEL-001 in liver transplantation, to accelerate development of its product pipeline across transplantation, neuroinflammatory and autoimmune diseases, and enhance its multi-modular engineered Treg platform.

            Lead Product(s): QEL-001

            Therapeutic Area: Immunology Product Name: QEL-001

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Jeito Capital

            Deal Size: $156.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing November 29, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The QEL-001 CAR is specific for HLA-A2, which localizes the activity of the CAR-Tregs to the site of the transplanted organ in HLA-A2 mismatch liver transplant patients (i.e. HLA-A2 negative recipients who received an HLA-A2 positive donor liver).

            Lead Product(s): Multi-modular Engineered Treg Cell Therapy

            Therapeutic Area: Immunology Product Name: QEL-001

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 27, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The milestone relates to pre-clinical development work on the SLN500 C3 targeting program, highlighting the successful ongoing collaboration between the two companies.

            Lead Product(s): SLN501

            Therapeutic Area: Immunology Product Name: SLN501

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Mallinckrodt Pharmaceuticals

            Deal Size: $2,020.0 million Upfront Cash: $20.0 million

            Deal Type: Collaboration April 28, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY